Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
In research, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori stands highest in Medicine (#3,986 of 10,443 worldwide) and Health Sciences (#5,472 of 11,982 worldwide), 2022–2025. Relative to its size it is most specialised in Oncology and Pulmonary and Respiratory Medicine — Oncology is 17.4× its share of world research.
- World rank, 2022–2025
- #9,554 of 28,054 · #10,719 all time
- Rank in Italy
- #272 of 618
- Research works
- 1.3k ▲ 73% vs 2013–17
- Citations
- 28k 21.2 per fractional work
- Top-10% rate
- 20.0% record average 16.5%
- Open access
- 43% world 28%
What is Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori known for in research?
The fields where it stands highest, 2022–2025, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works | All time |
|---|---|---|---|---|---|
| MedicineField | #3,986 of 10,443 | 19.0% | 186 | #2940 | |
| Health SciencesDomain | #5,472 of 11,982 | 18.9% | 189 | #4035 |
Each strip is that field’s whole ranked pool, with the notch where Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
What does Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori specialise in?
Where its research is concentrated relative to its size: Oncology takes 17.4× the share of its output that it takes of world research.
- OncologySubfield · 51.6 works17×
- Pulmonary and Respiratory MedicineSubfield · 34.4 works8.5×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 3.7×. Every wedge is a field page.
- Medicine 3.7×
- Biochemistry, Genetics and Molecular Biology 3.4×
- Immunology and Microbiology 2.6×
- Pharmacology, Toxicology and Pharmaceutics 0.7×
- Chemistry 0.6×
- Economics, Econometrics and Finance 0.5×
- Dentistry 0.3×
- Health Professions 0.3×
- Physics and Astronomy 0.2×
- Computer Science 0.2×
- Mathematics 0.1×
- Nursing 0.1×
- Neuroscience 0.1×
- Engineering 0.1×
- Business, Management and Accounting 0.1×
- Materials Science 0.1×
- Social Sciences 0.1×
- Veterinary 0.1×
- Decision Sciences 0.0×
- Agricultural and Biological Sciences 0.0×
- Environmental Science 0.0×
- Energy 0.0×
- Psychology 0.0×
Who are the top researchers at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori?
Ranked on the composite score, Angelo Delmonte, Ada Sacchi and Dino Amadori lead among researchers whose main affiliation is Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori.
- 1 Angelo Delmonte Italy · #154,311 worldwide 185 citations · 42 works
- 2 Ada Sacchi Italy · #188,910 worldwide 159 citations · 35 works
- 3 Dino Amadori Italy · #266,742 worldwide 99 citations · 45 works
- 4 Ugo De Giorgi Italy · #286,752 worldwide 274 citations · 121 works
- 5 Fabio Falcini Italy · #304,566 worldwide 125 citations · 61 works
- 6 Massimo Guidoboni Italy · #307,648 worldwide 108 citations · 28 works
- 7 Oriana Nanni Italy · #349,297 worldwide 103 citations · 51 works
- 8 Marco Maltoni Italy · #361,024 worldwide 52 citations · 30 works
- 9 Alberto Farolfi Italy · #380,238 worldwide 35 citations · 30 works
- 10 Giovanni Luca Frassineti Italy · #399,756 worldwide 77 citations · 35 works
Which keywords describe research at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Immunotherapy, Prognostic Factors, Targeted Therapy, Clinical Trials, Tumor Microenvironment, Biomarkers and Genetic Mutations.
- Hematopoietic Stem Cells
- Neoadjuvant Therapy
- Molecular Biology
- Androgen Receptor
- Metastatic Breast Cancer
- Mutational Signatures
- Somatic Mutations
- International Myeloma Working Group
- PET Imaging
- Immune Checkpoint Blockade
- Staging System
- Minimal Residual Disease
- Cancer Therapy
- Prostate Cancer
- Clinical Practice Guidelines
- Breast Cancer
- Biomarkers
- Cancer
- Clinical Trials
- Immunotherapy
- Chemotherapy
- Prognostic Factors
- Targeted Therapy
- Tumor Microenvironment
- Genetic Mutations
- Genomic Profiling
- Metastasis
- Survival Analysis
- Precision Medicine
- Proteasome Inhibitors
- Genomic Instability
- PD-1 and PD-L1
- Diagnosis Criteria
- Radiotherapy
- Cancer Genomics
- Hormone Therapy
- Molecular Subtypes
- Metastatic Prostate Cancer
- Molecular Characterization
- Cancer Immunotherapy
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy27▲ 15×21 topics
- Immunotherapy26▲ 14×18 topics
- Prognostic Factors24▲ 21×14 topics
- Clinical Trials20▲ 11×12 topics
- Targeted Therapy20▲ 34×4 topics
- Cancer17▲ 4.9×35 topics
- Tumor Microenvironment17▲ 14×8 topics
- Biomarkers16▲ 8.8×11 topics
- Genetic Mutations14▲ 12×11 topics
- Breast Cancer14▲ 22×10 topics
- Genomic Profiling13▲ 47×2 topics
- Clinical Practice Guidelines12▲ 8.4×12 topics
- Metastasis12▲ 13×9 topics
- Prostate Cancer12▲ 34×4 topics
- Survival Analysis11▲ 16×6 topics
- Cancer Therapy10▲ 6.9×12 topics
- Precision Medicine10▲ 8.5×7 topics
- Minimal Residual Disease10▲ 56×2 topics
- Proteasome Inhibitors10▲ 53×2 topics
- Staging System9▲ 58×2 topics
- Genomic Instability9▲ 31×3 topics
- Immune Checkpoint Blockade9▲ 31×1 topic
- PD-1 and PD-L19▲ 31×1 topic
- PET Imaging9▲ 20×5 topics
- Diagnosis Criteria9▲ 92×1 topic
- International Myeloma Working Group9▲ 92×1 topic
- Radiotherapy8▲ 8.4×12 topics
- Somatic Mutations8▲ 37×2 topics
- Cancer Genomics8▲ 41×1 topic
- Mutational Signatures8▲ 41×1 topic
- Hormone Therapy8▲ 36×3 topics
- Metastatic Breast Cancer8▲ 52×2 topics
- Molecular Subtypes8▲ 35×3 topics
- Androgen Receptor8▲ 40×2 topics
- Metastatic Prostate Cancer8▲ 71×1 topic
- Molecular Biology8▲ 70×1 topic
- Molecular Characterization7▲ 16×5 topics
- Neoadjuvant Therapy7▲ 11×5 topics
- Cancer Immunotherapy7▲ 17×3 topics
- Hematopoietic Stem Cells7▲ 29×3 topics
Which research topics does Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori publish most on?
By volume in 2022–2025: Cancer Immunotherapy and Biomarkers, Multiple Myeloma Research and Treatments, Cancer Genomics and Diagnostics and Prostate Cancer Treatment and Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Immunotherapy and Biomarkers Oncology 9 works
- 2 Multiple Myeloma Research and Treatments Hematology 9 works
- 3 Cancer Genomics and Diagnostics Cancer Research 8 works
- 4 Prostate Cancer Treatment and Research Pulmonary and Respiratory Medicine 8 works
- 5 Acute Myeloid Leukemia Research Hematology 6 works
- 6 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 5 works
- 7 Colorectal Cancer Treatments and Studies Oncology 5 works
- 8 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 5 works
- 9 Chronic Lymphocytic Leukemia Research Genetics 4 works
- 10 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 4 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori's research output changed?
Output in 2018–2022 was 73% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Meldola
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.